Cancer Test Co. Overpromised Insurer Coverage, Suit Says

By Emilie Ruscoe · December 6, 2023, 10:26 PM EST

Dermatologic test-maker DermTech Inc. and two of its executives have been hit with an investor's proposed class action alleging they misrepresented their expectations for securing reimbursement coverage broadly from commercial health...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Quarford v. Dermtech, Inc. et al

Case Number

Court

California Southern

Nature of Suit

Securities/Commodities

Date Filed

December 05, 2023

Recent Articles By Emilie

October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim
September 24, 2024
Biotech RenovaCare Investors Seek OK Of $2M Deal
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
August 02, 2024
Health Tech Co. Beats Investor Data Platform Fraud Claim
July 15, 2024
Ex-Pfizer Worker Seeks No Time For Paxlovid Insider Trading
May 20, 2024
Teladoc Faces Suit Over Mental Health Platform's Losses
May 14, 2024
Vein Tech Maker Faces Investor Suit Over DOJ Kickback Probe
April 19, 2024
AI Health Data Co. Faces Investor Suit Over Accounting Issues